PMID- 17725062
OWN - NLM
STAT- MEDLINE
DCOM- 20070926
LR  - 20220419
IS  - 0011-4162 (Print)
IS  - 0011-4162 (Linking)
VI  - 80
IP  - 1
DP  - 2007 Jul
TI  - Success of omalizumab as monotherapy in adult atopic dermatitis: case report and 
      discussion of the high-affinity immunoglobulin E receptor, FcepsilonRI.
PG  - 38-40
AB  - We report a case of a 41-year-old black man who presented with chronic severe 
      atopic dermatitis that only responded to oral corticosteroids. Failed treatments 
      for this patient included topical corticosteroids, topical pimecrolimus, oral 
      prednisone, oral antihistamines, azathioprine, and narrowband UV light therapy. 
      Only oral corticosteroids provided significant relief. The patient had an 
      immunoglobulin E (IgE) level of 7340 IU/mL (reference range, 0-100 IU/mL). He 
      responded to a 12-week course of omalizumab, a humanized monoclonal anti-LgE 
      antibody currently indicated for patients 12 years and older with moderate to 
      severe persistent asthma. Our patient experienced no adverse events throughout 
      the course of treatment. We suggest that omalizumab may have a role in the 
      treatment of isolated atopic dermatitis in the adult population.
FAU - Forman, Seth B
AU  - Forman SB
AD  - Medical College of Virginia Hospitals, Virginia Commonwealth University Health 
      System, Richmond, USA.
FAU - Garrett, Algin B
AU  - Garrett AB
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Cutis
JT  - Cutis
JID - 0006440
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Receptors, IgE)
RN  - 2P471X1Z11 (Omalizumab)
SB  - IM
MH  - Adult
MH  - Anti-Allergic Agents/*administration & dosage
MH  - Antibodies, Anti-Idiotypic
MH  - Antibodies, Monoclonal/*administration & dosage
MH  - Antibodies, Monoclonal, Humanized
MH  - Dermatitis, Atopic/*drug therapy/immunology
MH  - Humans
MH  - Injections, Subcutaneous
MH  - Male
MH  - Omalizumab
MH  - Receptors, IgE/*immunology
EDAT- 2007/08/30 09:00
MHDA- 2007/09/27 09:00
CRDT- 2007/08/30 09:00
PHST- 2007/08/30 09:00 [pubmed]
PHST- 2007/09/27 09:00 [medline]
PHST- 2007/08/30 09:00 [entrez]
PST - ppublish
SO  - Cutis. 2007 Jul;80(1):38-40.